Navigation Links
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Date:5/8/2008

in scores increased during placebo treatment and improved to values similar to sub-trial baseline (2.5 on the pain scale) when lacosamide was reintroduced. These findings indicate that, even after 16 months of treatment, lacosamide was still effectively treating pain.

Secondary endpoints indicated a worsening of pain when lacosamide was withdrawn. The intra-individual change in average daily pain score from open-label lacosamide treatment at baseline to the end of the placebo period was statistically significant (p<0.001). More subjects receiving placebo (39%) versus lacosamide (29%) experienced sustained worsening of pain during the withdrawal periods. Similarly, more subjects receiving placebo exited the withdrawal periods early due to increased pain than subjects receiving lacosamide (15% vs. 9%).

The trial revealed no new safety concerns with lacosamide, and there was also no evidence of withdrawal effects following abrupt discontinuation of lacosamide.

About lacosamide

Lacosamide has a dual mode of action and is the first agent of its kind to be clinically studied for the treatment of diabetic neuropathic pain. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target -- collapsin-response mediator protein-2 (CRMP-2). Lacosamide is also being investigated for its potential to treat partial onset seizures in adults with epilepsy.

Lacosamide oral tablet has been filed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of diabetic neuropathic pain. Applications for marketing authorization for lacosamide are supported by data from placebo-controlled clinical trials of more than 1,000 people with diabetic neuropathic pain. In these trials significant and sustained reductions in pain scores were seen versus placebo. The most common adverse events of lacosamide (greater than or equal to 10%) reported in these trials incl
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
2. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
3. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
4. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
5. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
8. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015  Organovo Holdings, Inc. (NYSE MKT: ... breakthrough 3D bioprinting technology, announced today that the company ... 2015 Healthcare Conference, to be held in ... Keith Murphy , Chairman and Chief Executive Officer, ... advances and partnerships. Details of the presentations ...
(Date:5/26/2015)... May 26, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that the Company,s President and ... present at the Jefferies 2015 Global Healthcare ... 11:30 a.m. EDT. Dr. Cauwenbergh will present ...
(Date:5/26/2015)... May 26, 2015 For the ... Quality of Life Throughout Europe, the Middle ... Astellas Pharma EMEA is celebrating its 10 ... through the historic merger of Japanese pharmaceutical companies Yamanouchi ... committed to turning science into value for patients through ...
Breaking Medicine Technology:Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 2Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 2RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 4Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4
... Sangart, Inc., a privately,held biopharmaceutical company focused ... today announced that it has,completed enrollment in a ... The completed study of 460 patients is ... conducted at 36 academic medical centers in the,United ...
... After completing its review of safety,and efficacy ... (DSMB) has once again recommended that the two ... FAME(TM) (Fluocinolone,Acetonide in Diabetic Macular Edema) Study can ... is studying the use of Medidur FA for,the ...
Cached Medicine Technology:Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan 2DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME 2DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME 3
(Date:5/26/2015)... 26, 2015 Abington is pleased ... a physician practice with seven medical professionals, has ... eighth primary-care site in the United States to ... home by the National Committee for Quality Assurance. ... preventative and sick care – including routine gynecology ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 Two ... recently joined Dr. Marissa Pei on a ... conversation focusing on addiction. Aired on KCAA AM 1050, ... Deena Duncan, marriage and family therapist, as they discuss ... estimated to affect more than 23.5 million Americans. The ...
(Date:5/26/2015)... May 26, 2015 CIO Review has chosen ... Promising Pharma and Life Sciences Technology Solution Providers. The positioning ... 11 compliant solution which is applicable across the entire security ... necessary for broad adoption. , “SIGNiX has been on ... the Pharma and Life Sciences Technology space, and we are ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week is ... by the Substance Abuse and Mental Health Services Administration ... action about, substance abuse as well as mental health ... to join in promoting prevention strategies, in educating other ... building community partnerships. , The Voice of One, the ...
(Date:5/26/2015)... Scientists at the University of Pennsylvania ... advanced mesothelioma patients benefit from immunotherapy; surgery may be ... on the new research. Click here to read ... thoracic surgery and pulmonology theorized that, because large mesothelioma ... attack, immunotherapy drugs might work better if the tumor ...
Breaking Medicine News(10 mins):Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2
... Nov. 12 Governor Jennifer M.,Granholm, Attorney General ... Barrett today kicked off the 4th Annual "Support ... raises funds to,support Michigan soldiers, sailors, and Marines ... benefit the Bob Woodruff Family,Fund founded by Michigan ...
... personalized portal for referring ... ... AMCS ),a leader in radiology and medical image and information management,solutions, ... that can help imaging businesses grow by attracting,referrals and securing referring ...
... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the ... both consumers and businesses, today announced that it,has ... will report results for its third quarter ended ... on Wednesday, November 14, 2007 and,will host a ...
... may be tied to weight , , MONDAY, Nov. 12 (HealthDay ... health problems, new research suggests that fat men are twice ... than men of normal weight. , The research doesn,t confirm ... death from prostate cancer, and it,s not clear if losing ...
... researchers have developed a small molecule that can turn the ... death signal. The molecule mimics the activity of Smac, a ... cells. ,The researchers say their findings suggest that Smac-mimetic ... and other cancers. Such therapy may be less toxic to ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
Cached Medicine News:Health News:Governor Granholm, Attorney General Cox, & Michigan Chamber Kick Off 4th Annual 'Support MI Troops' Fundraising Drive Proceeds to Benefit the Bob Woodruff Family Fund 2Health News:AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow 2Health News:AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow 3Health News:eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call 2Health News:Obesity Linked to Prostate Cancer Death Rates 2Health News:Obesity Linked to Prostate Cancer Death Rates 3Health News:Smac-ing lung cancer to death 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4
Inquire...
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
Silicone Compression Mat, Bulk...
MicroAmp Full Plate Covers, which are manufactured from PCR-compatible rubber, are non-sterile, autoclavable and guaranteed reusable up to five times....
Medicine Products: